James Dongjoo Ham

TL;DR: Current challenges and future promise of CAR-NK cells as a novel cellular immunotherapy in cancer are discussed, and they could be engineered to target diverse antigens, enhance proliferation and persistence in vivo, increase infiltration into solid tumours, overcome resistant tumour microenvironment, and ultimately achieve an effective anti-tumour response.

TL;DR: Efficient arming of CIML NK cells with a neoepitope-specific chimeric antigen receptor (CAR) significantly enhances their antitumor responses to nucleophosphmin-1 (NPM1)-mutated AML while avoiding off-target toxicity.

TL;DR: This work utilized a new approach to arm NK cells for adoptive immunotherapy based on innate cell memory and overcome the transduction block in primary human and mouse NK cells by utilizing an unconventional pseudotyped lentivirus based on a unique protein with high expression on CIML NK cells.

TL;DR: It is shown that ascites and CA125 inhibit antitumor activity of NK cells at transcriptional levels by suppressing expression of genes involved in NK cell activation and cytotoxicity.

TL;DR: In this article , the homologous recombination pathway component RAD51B was identified as an essential gene in near-haploid leukemia, and DNA damage analyses revealed significantly increased sensitivity of RAD51-mediated repair to RAD51b loss in the G2/M stage.